EWTX$20.415
Chart
Performance
Key Stats
AI EWTX Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyEdgewise Therapeutics shows promising potential in the biopharmaceutical sector, with a focus on muscle disorders. While it exhibits some fundamental strengths, particularly in its pipeline and low debt, its profitability and current valuation metrics indicate room for improvement. Technical indicators suggest a currently bearish short-term outlook. Long-term investors may find value, but caution is advised due to current market sentiment and valuation.
Thematic
Edgewise Therapeutics is positioned in the growing field of precision medicine for muscle disorders. Its focus on unmet medical needs, particularly Duchenne muscular dystrophy and hypertrophic cardiomyopathy, presents a significant thematic opportunity. The company's commitment to innovative drug development aligns with current healthcare trends.
Fundamental
Edgewise Therapeutics has a solid balance sheet with minimal debt, but currently reports no revenue and significant net losses. Its future financial performance is heavily dependent on the success of its clinical pipeline.
Technical
The stock is currently trading below its key moving averages and shows weak short-term momentum. While the long-term trend may be in development, current technical indicators suggest a bearish outlook with potential for further downside.
| Factor | Score |
|---|---|
| Biopharmaceutical Innovation | 85 |
| Market Focus - Muscle Disorders | 80 |
| Precision Medicine Trend | 90 |
| Regulatory Environment (Pharma) | 60 |
| Biotech Funding Environment | 70 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Profitability | 10 |
| Growth | 0 |
| Balance Sheet Health | 95 |
| Cash Flow | 15 |
| Factor | Score |
|---|---|
| Trend Analysis | 30 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Strong Cash Position
The company has $41.666 million in cash and cash equivalents as of 2024Q4, providing a cushion for operational needs and potential investments.
Positive Short-Term Performance
The stock has shown a 5-day performance of -3.95%, 1-month performance of -7.66%, indicating recent price movements.
Bearish Points (9)
Significant Long-Term Underperformance
The stock has experienced substantial declines over longer periods, with 6-month performance at -49.93%, Year-to-Date at -50.5%, and 1-year performance at -37.74%.
Negative Free Cash Flow
The company has consistently reported negative free cash flow (e.g., -110.34 million in 2024Q4), indicating it is spending more cash than it generates from operations and investments.
Calendar
August 2025
6
Next Earnings Date
H: $-0.38
A: $-0.42
L: $-0.48
Profile
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Seasonals
Price Target
38.82 USD
The 39 analysts offering 1 year price forecasts for EWTX have a max estimate of 51.00 and a min estimate of 14.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Seres Therapeutics is a leading public microbiome company, making it a direct peer and competitor to Evelo Biosciences in the development of gut-axis therapeutics for inflammatory diseases.
Weight: 90
Another public company focused on microbiome therapeutics, Finch Therapeutics also faced significant challenges and restructuring, highlighting the shared market dynamics and difficulties in this innovative space.
Weight: 88
AbbVie is a dominant player in inflammatory diseases, including inflammatory bowel disease (IBD) and psoriasis, which were key therapeutic targets for Evelo Biosciences. Their market presence makes them a major stakeholder in the diseases Evelo was addressing.
Weight: 87
Johnson & Johnson is a major pharmaceutical company with a robust immunology pipeline, offering several drugs for inflammatory bowel disease and psoriasis, aligning with Evelo's target therapeutic areas.